SAB Biotherapeutics
SABS
34 hedge funds and large institutions have $56.3M invested in SAB Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 4 closing their positions.
1,572% more capital invested
Capital invested by funds: $3.37M → $56.3M (+$53M)
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
248.46% more ownership
Funds ownership: 20.71% → 269.17% (+248%)
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
36% more funds holding
Funds holding: 25 → 34 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$25.8M |
| 2 |
CC
Commodore Capital
New York
|
+$9.95M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$9.95M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$6.45M |
| 5 |
SC
Sessa Capital
New York
|
+$3.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$29.9K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$20.8K |
| 3 |
S
Sachetta
Lynnfield,
Massachusetts
|
-$7.2K |
| 4 |
BlackRock
New York
|
-$1.51K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$255 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $3.14K | +$1.89K | +834 | +115% |
|
27
Citigroup
New York
| $1.67K | +$1.88K | +832 | New |
|
|
MCM
28
MAI Capital Management
Independence,
Ohio
| $437 | – | – | – |
|
|
GI
29
GS Investments
Minneapolis,
Minnesota
| $402 | – | – | – |
|
30
Morgan Stanley
New York
| $338 | – | – | – |
|
31
JP Morgan Chase
New York
| $175 | – | – | – |
|
32
Bank of America
Charlotte,
North Carolina
| $149 | +$2 | +1 | +1% |
|
|
SS
33
SBI Securities
Tokyo,
Japan
| $105 | +$5 | +2 | +4% |
|
|
HI
34
Harbour Investments
Madison,
Wisconsin
| $101 | – | – | – |
|
|
35
Citadel Advisors
Miami,
Florida
| – | -$29.9K | -17,095 | Closed |
|
|
36
Creative Planning
Overland Park,
Kansas
| – | -$20.8K | -11,852 | Closed |
|
|
S
37
Sachetta
Lynnfield,
Massachusetts
| – | -$7.2K | -4,100 | Closed |
|
38
Raymond James Financial
St Petersburg,
Florida
| – | -$79 | -45 | Closed |
|
SABS Hedge Fund Activity: Q3 2025 in Review
34 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q3 2025, worth a combined $56.3M — up 1,572% from $3.37M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SABS positions and 4 closed out — a net gain of 9 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $25.8M. The largest seller was Citadel Advisors, exiting entirely with an estimated $29.9K sold.
- 34 institutional investors held SAB Biotherapeutics (SABS) as of Q3 2025, up from 25 in Q2 2025.
- Funds reported $56.3M of SAB Biotherapeutics stock for Q3 2025, up 1,572% quarter-over-quarter.
- 13 funds opened new SAB Biotherapeutics positions in Q3 2025 and 4 closed out, a net change of +9 holders.
- The largest SAB Biotherapeutics buyer in Q3 2025 was Vivo Capital, an estimated $25.8M added.
- The largest SAB Biotherapeutics seller in Q3 2025 was Citadel Advisors, an estimated $29.9K sold.
Based on aggregated 13F filings for Q3 2025.